Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma.

Disease models & mechanisms - 1 Jan 2000

Politi Katerina, Fan Pang-Dian, Shen Ronglai, Zakowski Maureen, Varmus Harold

Abstract excerpt

Seventy-five percent of lung adenocarcinomas with epidermal growth factor receptor (EGFR) mutations respond to treatment with the tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib; however, drug-resistant tumors eventually emerge. In 60% of cases, resistant tumors carry a secondary mutati...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Drug Resistance, Neoplasm
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Erlotinib Hydrochloride

Share to Gene Amplification

Share to Proto-Oncogene Proteins c-met

Share to Quinazolines

Share to Transgenes

Source

Open in PubMed Open full text

Identifiers

PMID: 20007486
DOI: 10.1242/dmm.003681
PMCID: PMC2806903

Genes

EGFR
MET

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20007486-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma.PMID 20007486Read ↗

Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer.Semantic proximity Read ↗

Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors.Semantic proximity Read ↗

Generation of genetically engineered mice for lung cancer with mutant EGFR.Semantic proximity Read ↗

EGFR: The Paradigm of an Oncogene-Driven Lung Cancer.Semantic proximity Read ↗

Combined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers codriven by mutant EGFR containing T790M and MET.Semantic proximity Read ↗

Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance EGFR Mutations.Semantic proximity Read ↗

Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung Adenocarcinoma.Semantic proximity Read ↗

Modeling acquired TKI resistance and effective combination therapeutic strategies in murine RET+ lung adenocarcinomaSemantic proximity Read ↗

EGF receptor mutations in lung cancer: from humans to mice and maybe back to humans.Semantic proximity Read ↗

Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1.Semantic proximity Read ↗

Acquired Resistance to Erlotinib in EGFR Mutation-Positive Lung Adenocarcinoma among Hispanics (CLICaP).Semantic proximity Read ↗

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase DomainSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.